Your shopping cart is currently empty

Furaprofen is an orally available, selective and potent HCV inhibitor with anti-inflammatory activity, inhibits carrageenan-induced paw edema in rats and inhibits cotton pellet-induced granulomas in rats at higher doses.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $289 | In Stock | In Stock | |
| 5 mg | $689 | In Stock | In Stock | |
| 10 mg | $987 | In Stock | In Stock | |
| 25 mg | $1,520 | In Stock | In Stock | |
| 50 mg | $1,980 | In Stock | In Stock |
| Description | Furaprofen is an orally available, selective and potent HCV inhibitor with anti-inflammatory activity, inhibits carrageenan-induced paw edema in rats and inhibits cotton pellet-induced granulomas in rats at higher doses. |
| Targets&IC50 | HCV 1a/1b:(EC50)~30 nM, HCV 2a:~1000 nM(EC50) |
| In vitro | The effectiveness of Furaprofen in inhibiting the replicon is verified through Western blotting and TaqMan RT-PCR, yielding IC50 values of approximately 37 nM and 54.67±4.11 nM, respectively. Furthermore, its antiviral potency, assessed via a reporter replicon assay conducted through multiple iterations, demonstrates a significant increase, standing at 29.88±8.05 nM—indicating an approximately threefold enhancement when compared to its precursor compound, R706. To evaluate Furaprofen's broader impact on cell proliferation, diverse primary and transformed human cell lines were subjected to escalating doses of the compound over a 48-hour period. The resultant effect on cell proliferation was quantified using an MTS-based cell viability assay, revealing the CC50 (the concentration required to diminish cell numbers by 50% in the absence of viral infection) of Furaprofen to vary between 2 μM and ≥10 μM, contingent upon the specific cell type and its proliferation state[1]. |
| Synonyms | R-803, R803, R 803 |
| Molecular Weight | 266.29 |
| Formula | C17H14O3 |
| Cas No. | 67700-30-5 |
| Smiles | CC(C(O)=O)c1cccc2c(coc12)-c1ccccc1 |
| Relative Density. | 1.23g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 200 mg/mL (751.06 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (18.78 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.